Skip to main content

Injectable Drug Delivery Market to Exhibit a Remarkable CAGR of 12.9% and to Cross USD 1251.28 Billion by 2026, Shift from Traditional Syringes to Reusable Syringes Contributes to the Market Growth

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, India, March 17, 2021 (GLOBE NEWSWIRE) — A study by the American Diabetes Association (ADA) has found that around 30.3 million people in the U.S. were diagnosed with diabetes. The rising prevalence of chronic diseases such as diabetes, cancer, and others is boosting the global injectable drug delivery market. Fortune Business Insights in a report, titled “INJECTABLE DRUG DELIVERY MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2027” predicts the global market to rise at a remarkable CAGR of 12.9% during the forecast period. The global market was worth USD 483.55 Billion in 2019, and by the end of 2027, the market is anticipated to reach USD 1251.28 Billion.Introduction of Novel Injectable Drug Delivery to Propel Growth in North AmericaCurrently, the market in North America is exhibiting the highest CAGR owing to the rapid adoption of advanced and innovative injectable drug delivery. Moreover, injectable drug users are increasing as these devices are preferred owing to their therapeutic and convenience benefits. The amplified prevalence of chronic disorders such as cancer, diabetes, and others is driving the injectable drug delivery market size in North America.As per the National Cancer Institute, around 1,735,350 cancer cases were registered in the U.S. With the help of an injectable device; chemotherapy drugs are delivered to cancer patients with ease. Another factor responsible for injectable drug delivery growth is the presence of major manufacturers in North America. This further increases the adoption of injectable drug delivery systems.
Request a Sample Copy of the Global Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/injectable-drug-delivery-market-101044
These manufacturers are planning to develop innovative drug delivery such as auto-injectors, smart wearables, among others in the years to come. Against this backdrop, the market is likely to grow in the forecast period in North America. As per the report, the market was valued at US$ 156.8 Bn in the year 2018.Advances in Injectable Drug Devices Focuses on Simplifying their Usage in Complex Procedures“Traditional drug delivery are more prone to infections owing to their mishandling. This can be minimized by adopting reusable glass syringes and pre-filled syringes,” said a lead analyst at Fortune Business Insights. “These smart and advanced devices have proven to be highly effective and safe for humans, which fuels their demand in the market,” he added.Advances in technology and design of injectable drug delivery are aimed at simplifying their usage during complex drug delivery procedures. The introduction of next-generation drug delivery offering high-quality and superior functionalities acts as a potential growth trigger. Such technological improvements will enhance patient compliance and simultaneously make it easier for clinicians to perform the injectable drug delivery procedure. This, together with the rising focus on biologics in the pharmaceutical sector, is anticipated to facilitate growth in the market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/injectable-drug-delivery-market-101044
BD Leads the Market Owing to its Vast Product PortfolioAmong key players, Becton Dickinson boasts an innovative and vast product portfolio which includes pen-injectors, auto-injectors, and others. The company is leading in the global injectable drug delivery market, mainly on account of its global presence.Other companies are focusing on product innovations to expand their market shares. The key players profiled in the report are SHL Group, BD, Insulet Corporation, Pfizer Inc., Eli Lilly and Company, Elcam Medical, Ypsomed AG, West Pharmaceutical Services, Inc., and Gerresheimer AG. Of these, BD, SHL, and Insulet Corporation hold the maximum share in the global market. The strong presence of these companies will surge the injectable drug delivery revenue in the forecast years. Some of the notable industry developments made by companies which will help the market
Quick Buy Injectable Drug Delivery Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101044
West Pharmaceutical Services, Inc., launched a new extension of SMARTDOSE drug delivery platform in November 2017.AbbVie Inc. and Eisai Co., Ltd., together announced the launch of an auto-injector device in June 2018. This device is for Humira drug for the treatment of autoimmune diseases.EVER NEURO PHARMA GMBH launched D-MINE pump for patients suffering from Parkinson’s disease in July 2019.  The device is convenient to use and aims to provide continuous subcutaneous drug delivery.
List of players leading the global Injectable Drug Delivery Market include:SHL Group ABBDInsulet CorporationPfizerEli Lilly and CompanyElcam MedicalYpsomed AGWest Pharmaceutical ServicesGerresheimer AG
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/injectable-drug-delivery-market-101044
Detail Table of Content:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsPrevalence of key diseases – For key countries, 2018New product launchOverview of technological advancements in injectable drug deliveryPricing analysisKey Industry Developments – Mergers, Acquisitions, and Partnerships, 2018Global Injectable Drug Delivery Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis, Insights and Forecast – By Device TypeConventional InjectablePre-filled SyringesAuto-injectorsPen-injectorsOthersMarket Analysis, Insights and Forecast – By ApplicationAutoimmune DisordersDiabetesPain ManagementAesthetic TreatmentsOthersMarket Analysis, Insights and Forecast – By Route of AdministrationSubcutaneousIntravenousIntramuscularOthersMarket Analysis, Insights and Forecast – By End-UserHospitalsHome Care SettingsClinicsOthersMarket Analysis, Insights and Forecast – By RegionNorth AmericaEuropeAsia pacificLatin AmericaMiddle East & AfricaNorth America Injectable Drug Delivery Market Analysis, Insights and Forecast, 2015-2026Key Findings / SummaryMarket Analysis – By Device TypeConventional InjectablePre-filled SyringesAuto-injectorsPen-injectorsOthersMarket Analysis – By ApplicationAutoimmune DisordersDiabetesPain ManagementAesthetic TreatmentsOthersMarket Analysis – By Route of AdministrationSubcutaneousIntravenousIntramuscularOthersMarket Analysis – By End-UserHospitalsHome Care SettingsClinicsOthersMarket Analysis – By CountryU.S.CanadaTOC Continued…!!
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/injectable-drug-delivery-market-101044
Have a Look at Related Reports:E-prescribing Market Size, Share & Industry Analysis, By Delivery Mode (Web-based, On-premise), By Prescription Type (Controlled substance, Non controlled Substances) By End User (Hospitals, Physician’s offices, Pharmacies) and Regional Forecast, 2019-2Dental Crowns and Bridges Market Size, Share & Industry Analysis, By Type (Crowns, and Bridges), By Material (Ceramics, Porcelain Fused to Ceramics, and Metals), By End User (Dental Hospitals & Clinics, Dental Laboratories, and Others), and Regional Forecast, 2019-2026MicroRNA Market Size, Share & Covid-19 Impact Analysis, By Product (Instruments and Kits & Reagents) By Application (Isolation & Purification, Detection & Quantification, Disease Diagnostics, and Others) and By End User (Pharma & Biotech Companies, Academic & Research Institutes, Healthcare Facilities, and Others), Regional Forecast, 2020-2027Foot Orthotic Insoles Market Size, Share & COVID-19 Impact Analysis, By Type (Prefabricated and Customized), By Application (Medical, Sports & Athletics, and Personal), By Material (Thermoplastics, Ethyl-vinyl Acetate (EVA), Foam, Composite Carbon Fiber, and Others), By Age Group (Pediatrics and Adults), By Distribution Channel (Hospital Pharmacies, Retail Stores, and Online Stores), and Regional Forecast, 2020-2027
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press: https://www.fortunebusinessinsights.com/press-release/injectable-drug-delivery-market-9202

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.